A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT ID: NCT07018323
Last Updated: 2026-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
210 participants
INTERVENTIONAL
2025-06-19
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
NCT07286006
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
NCT05907668
Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz
NCT06240455
In Vivo CAR-T for Refractory Graves' Disease
NCT07333677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IMVT-1402 Dose 1
IMVT-1402
Dose 1 for 26 weeks
IMVT-1402 Dose 2
IMVT-1402
Dose 2 for 26 weeks
Placebo
Placebo
For 26 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IMVT-1402
Dose 1 for 26 weeks
IMVT-1402
Dose 2 for 26 weeks
Placebo
For 26 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female participants aged ≥ 18 years.
* Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.
Exclusion Criteria
* Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk.
* Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Immunovant Sciences GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Number - 1015
Tucson, Arizona, United States
Site Number -1014
Concord, California, United States
Site Number - 1013
Aurora, Colorado, United States
Site Number - 1024
Doral, Florida, United States
Site Number - 1008
Hialeah, Florida, United States
Site Number - 1000
Miami, Florida, United States
Site Number - 1020
Columbus, Georgia, United States
Site Number - 1022
Topeka, Kansas, United States
Site Number - 1033
Jefferson City, Missouri, United States
Site Number - 1004
Kansas City, Missouri, United States
Site Number - 1019
St Louis, Missouri, United States
Site Number - 1012
Reno, Nevada, United States
Site Number - 1032
Long Island City, New York, United States
Site Number - 1027
New Hyde Park, New York, United States
Site Number - 1009
New York, New York, United States
Site Number - 1018
Williamsville, New York, United States
Site Number - 1010
Chapel Hill, North Carolina, United States
Site Number - 1026
Hickory, North Carolina, United States
Site Number - 1001
Morehead City, North Carolina, United States
Site Number - 1034
Raleigh, North Carolina, United States
Site Number - 1007
Oklahoma City, Oklahoma, United States
Site Number - 1017
Memphis, Tennessee, United States
Site Number - 1029
Dallas, Texas, United States
Site Number - 1002
El Paso, Texas, United States
Site Number - 1003
Fort Worth, Texas, United States
Site Number - 1031
Houston, Texas, United States
Site Number - 1028
Houston, Texas, United States
Site Number -1023
Irving, Texas, United States
Site Number - 1021
Irving, Texas, United States
Site Number - 1025
McKinney, Texas, United States
Site Number - 1011
San Antonio, Texas, United States
Site Number - 1016
Norfolk, Virginia, United States
Site Number - 5105
Sydney, New South Wales, Australia
Site Number - 5103
Warrawong, New South Wales, Australia
Site Number - 5101
Brisbane, Queensland, Australia
Site Number - 5100
Southport, Queensland, Australia
Site Number - 5104
Geelong, Victoria, Australia
Site Number - 5108
Perth, , Australia
Site Number - 5109
Saint Leonards, , Australia
Site Number - 5613
Dobrich, , Bulgaria
Site Number - 5606
Plovdiv, , Bulgaria
Site Number - 5607
Plovdiv, , Bulgaria
Site Number - 5601
Sliven, , Bulgaria
Site Number - 5612
Smolyan, , Bulgaria
Site Number - 5604
Sofia, , Bulgaria
Site Number - 5609
Sofia, , Bulgaria
Site Number - 5608
Sofia, , Bulgaria
Site Number - 5602
Varna, , Bulgaria
Site Number - 5603
Varna, , Bulgaria
Site Number - 5611
Varna, , Bulgaria
Site Number - 5600
Yambol, , Bulgaria
Site Number - 3203
Náchod, , Czechia
Site Number - 3201
Prague, , Czechia
Site Number - 3200
Prague, , Czechia
Site Number - 3202
Prague, , Czechia
Site Number - 8004
Imereti, , Georgia
Site Number - 8003
Tbilisi, , Georgia
Site Number - 8000
Tbilisi, , Georgia
Site Number - 8002
Tbilisi, , Georgia
Site Number - 8001
Tbilisi, , Georgia
Site Number - 8005
Tbilisi, , Georgia
Site Number - 3902
Athens, , Greece
Site Number - 3900
Athens, , Greece
Site Number - 3901
Athens, , Greece
Site Number - 4202
Ramat Gan, Central District, Israel
Site Number - 4205
Haifa, Haifa District, Israel
Site Number - 4203
Haifa, Haifa District, Israel
Site Number - 4209
Nahariya, Northern District, Israel
Site Number - 4206
Tzfat, Northern District, Israel
Site Number - 4211
Beersheba, Southern District, Israel
Site Number - 4201
Jerusalem, , Israel
Site Number - 4204
Jerusalem, , Israel
Site Number - 4200
Petah Tikva, , Israel
Site Number - 4207
Tel Aviv, , Israel
Site Number - 4600
Ogre, , Latvia
Site Number - 4602
Riga, , Latvia
Site Number - 4603
Riga, , Latvia
Site Number - 4604
Sigulda, , Latvia
Site Number - 4601
Ventspils, , Latvia
Site Number - 3301
Auckland, , New Zealand
Site Number - 3300
Wellington, , New Zealand
Site Number - 3002
Bydgoszcz, , Poland
Site Number - 3010
Chorzów, , Poland
Site Number - 3007
Kielce, , Poland
Site Number - 3000
Lublin, , Poland
Site Number - 3005
Olsztyn, , Poland
Site Number - 3009
Opole, , Poland
Site Number - 3006
Poznan, , Poland
Site Number - 3008
Warsaw, , Poland
Site Number - 4500
Daegu, , South Korea
Site Number - 4503
Goyang, , South Korea
Site Number - 4504
Guri-si, , South Korea
Site Number - 4501
Seoul, , South Korea
Site Number - 4506
Seoul, , South Korea
Site Number - 4505
Seoul, , South Korea
Site Number - 7009
Cornwell, , United Kingdom
Site Number - 7001
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-521920-31-00
Identifier Type: CTIS
Identifier Source: secondary_id
IMVT-1402-2503
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.